Deal closes on schedule in second half of 2026
The shareholder vote was the largest remaining hurdle. With antitrust review of two complementary—not overlapping—diagnostics businesses unlikely to face serious objection, the transaction closes in Q3 or Q4 2026 as Danaher has guided. Masimo becomes a standalone operating company inside Danaher's Diagnostics segment, and Danaher books the projected $125 million in annual cost synergies starting in year five.
